In stages 3–4 (established CVD/CKD), antioxidants may have limited effects due to irreversible organ damage, but combining them with other therapies (e.g., statins or SGLT2 inhibitors) can enhance benefits (32). Here, SLC5A2 is linked to chronic kidney disease.